Substituted cysteine accessibility of the third transmembrane domain of the creatine transporter: defining a transport pathway.
Twenty-two amino acid residues from transmembrane domain 3 of the creatine transporter were replaced, one at a time, with cysteine. The background for mutagenesis was a C144S mutant retaining approximately 75% of wild-type transport activity but resistant to methanethiosulfonate (MTS) reagents. Each substitution mutant was tested for creatine transport activity and sensitivity to the following MTS reagents: 2-aminoethyl methanethiosulfonate (MTSEA), 2-(trimethylammonium) ethyl methanethiosulfonate (MTSET), and 2-sulfonatoethyl methanethiosulfonate (MTSES). Two mutants (G134C and Y148C) were inactive, but most mutants showed significant levels of creatine transport. Treatment with MTSEA inhibited the activity of the W154C, Y147C, and I140C mutants. Creatine partially protected I140C from inactivation, and this residue, like Cys-144 in the wild-type CreaT, is predicted to be close to a creatine binding site. MTSEA inactivation of Y147C was dependent on Na+ and Cl- suggesting that solvent accessibility was ion-dependent. Helical wheel and helical net projections indicate that the three MTSEA-sensitive mutants (W154C, Y147C, and I140C) and two inactive mutants (V151C and Y148C) are aligned on a face of an alpha-helix, suggesting that they form part of a substrate pathway. The W154C mutant, located near the external face of the membrane, was accessible to the larger MTS reagents, whereas those implicated in creatine binding were only accessible to the smaller MTSEA. Consideration of our data, together with a study on the serotonin transporter (Chen, J. G., Sachpatzidis, A., and Rudnick, G. (1997) J. Biol. Chem. 272, 28321-28327), suggests that involvement of residues from transmembrane domain 3 is a common feature of the substrate pathway of Na+- and Cl- -dependent neurotransmitter transporters.
Dodd
Joanna R
JR
Cell Biology and Biochemistry Section, School of Biological Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.
Christie
David L
DL
D000595:Amino Acid Sequence; D001665:Binding Sites; D001692:Biological Transport; D019921:Biotinylation; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D002713:Chlorine / Q000494:pharmacology; D003401:Creatine / Q000737:chemistry / Q000378:metabolism*; D003545:Cysteine / Q000737:chemistry*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007477:Ions; D026901:Membrane Transport Proteins / Q000737:chemistry* / Q000502:physiology*; D008698:Mesylates / Q000494:pharmacology; D008954:Models, Biological; D008969:Molecular Sequence Data; D016296:Mutagenesis; D009154:Mutation; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D012964:Sodium / Q000737:chemistry / Q000494:pharmacology; D012997:Solvents / Q000494:pharmacology; D013439:Sulfhydryl Reagents / Q000494:pharmacology; D013997:Time Factors; D014162:Transfection
D007477:Ions; D026901:Membrane Transport Proteins; D008698:Mesylates; D012997:Solvents; D013439:Sulfhydryl Reagents; C080679:creatine transporter; C109153:(2-sulfonatoethyl)methanethiosulfonate; C109154:(2-(trimethylammonium)ethyl)methanethiosulfonate; C074502:methanethiosulfonate; D002713:Chlorine; D012964:Sodium; D003545:Cysteine; D003401:Creatine